首页> 外文会议>World Congress on Medical Physics and Biomedical Engineering >Engineering Safety Study of a Circuit Conducting Simultaneous Hemodialysis and Plasma Exchange
【24h】

Engineering Safety Study of a Circuit Conducting Simultaneous Hemodialysis and Plasma Exchange

机译:同时进行血液透析和血浆置换的电路的工程安全性研究

获取原文

摘要

Clinical reports have stated that hemodialysis and experimental plasma exchange must be carried out at the same time. In reality, these medical treatments are performed separately, which increases the course of the patient's treatment. To shorten the duration of treatment and improve patients' quality of life, we developed a circuit for simultaneous hemodialysis and experimental plasma exchange. The aim of the current study was investigate the engineering safety of this hemodialysis and plasma exchange circuit. The circuit (DFPP-21-HD), a hemodialyzer (DBB-72), plasma exchange equipment (Pulasort iQ21), a dialyzer (PS-1.6N), a plasma separator (Plasmacure PE08), and a second filter (Evafiux 2A-F) were used in the study. Double-filtration plasmapheresis (DFFP) was selected for the experimental plasmapheresis mode. Priming volume and pressure were measured using the circuit aqueous solution's coefficient of viscosity, and the damage to blood cells in the extended circuit was evaluated using cattle blood (5 liters at 40% hematocrit). The priming volume for the DFPP-21-HD circuit was 182 ml. The circuit pressure was measured by changing the flow, mirroring values at 40% hematocrit, which was prepared by adjusting the viscosity of the aqueous solution. Blood cell damage was investigated at a blood flow of 100 ml/min and a separator flow of 30 ml/min. Arterial blood samples were obtained at 15-tnin intervals for seven cycles. There were minimal changes in the serum potassium level and the hematocrit. This study demonstrates minimal blood cell damage due to priming volume and circuit pressure variations, indicating little danger to the patient. Circuit DFPP-21-HD is a safe technical design that can be applied for clinical hemodialysis and plasmapheresis.
机译:临床报告指出,血液透析和实验血浆交换必须同时进行。实际上,这些医学治疗是分开进行的,这增加了患者的治疗过程。为了缩短治疗时间并改善患者的生活质量,我们开发了一种同时进行血液透析和血浆置换实验的电路。本研究的目的是研究这种血液透析和血浆交换回路的工程安全性。电路(DFPP-21-HD),血液透析仪(DBB-72),血浆交换设备(Pulasort iQ21),透析仪(PS-1.6N),血浆分离器(Plasmacure PE08)和第二个过滤器(Evafiux 2A) -F)用于研究。选择双滤血浆置换(DFFP)作为实验血浆置换模式。使用回路水溶液的粘度系数测量灌注体积和压力,并使用牛血(40%血细胞比容下5升)评估延伸回路中血细胞的损伤。 DFPP-21-HD回路的灌注体积为182 ml。通过改变流量,在40%血细胞比容下的镜像值来测量回路压力,这是通过调节水溶液的粘度来制备的。在100 ml / min的血流量和30 ml / min的分离器流量下研究血细胞损伤。以15次/分钟的间隔获取动脉血样品,共进行七个周期。血清钾水平和血细胞比容变化很小。这项研究表明,由于灌注量和回路压力变化而导致的血细胞损害最小,对患者几乎没有危险。 DFPP-21-HD电路是一种安全的技术设计,可用于临床血液透析和血浆置换。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号